CHRONOS - A Multicenter, Non - Interventional Study to Observe the Safety and Efficacy of Vedolizumab (Entyvio) in Patients With Ulcerative Colitis or Crohn´s Disease That Are Biologic naïve, Observed in Daily Practice in Austria
Phase of Trial: Phase IV
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHRONOS
- Sponsors Takeda
- 13 Feb 2018 Planned End Date changed from 1 Nov 2018 to 31 Aug 2020.
- 13 Feb 2018 Planned primary completion date changed from 1 Nov 2017 to 31 Aug 2020.
- 19 Jan 2017 Status changed from not yet recruiting to recruiting.